-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
GH Research (NASDAQ:GHRS) Shares Gap Up to $9.65
GH Research (NASDAQ:GHRS) Shares Gap Up to $9.65
GH Research PLC (NASDAQ:GHRS – Get Rating)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $9.65, but opened at $10.10. GH Research shares last traded at $10.10, with a volume of 5 shares trading hands.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on GHRS shares. UBS Group assumed coverage on GH Research in a research report on Thursday, December 15th. They set a "buy" rating on the stock. EF Hutton Acquisition Co. I initiated coverage on GH Research in a research report on Friday, December 16th. They set a "buy" rating and a $33.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $46.25.
Get GH Research alerts:GH Research Trading Up 0.1 %
The stock has a market capitalization of $488.03 million, a price-to-earnings ratio of -48.27 and a beta of 0.96. The company's 50 day moving average is $10.40 and its 200 day moving average is $11.55.
GH Research (NASDAQ:GHRS – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.16. Analysts anticipate that GH Research PLC will post -0.42 EPS for the current fiscal year.Institutional Trading of GH Research
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its holdings in GH Research by 277.1% during the third quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the company's stock worth $39,000 after buying an additional 2,486 shares in the last quarter. Tortoise Investment Management LLC acquired a new position in GH Research during the second quarter worth about $41,000. Exchange Traded Concepts LLC raised its position in GH Research by 373.4% during the second quarter. Exchange Traded Concepts LLC now owns 4,885 shares of the company's stock worth $49,000 after acquiring an additional 3,853 shares during the last quarter. Bank of America Corp DE raised its position in GH Research by 31,790.0% during the first quarter. Bank of America Corp DE now owns 6,378 shares of the company's stock worth $116,000 after acquiring an additional 6,358 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its position in GH Research by 48.8% during the second quarter. Virtus ETF Advisers LLC now owns 9,952 shares of the company's stock worth $99,000 after acquiring an additional 3,265 shares during the last quarter. Hedge funds and other institutional investors own 62.55% of the company's stock.
About GH Research
(Get Rating)
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
- Get a free copy of the StockNews.com research report on GH Research (GHRS)
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
周三开盘前,GH Research PLC(纳斯达克代码:GHRS-GET Rating)的股价出现跳水。该股此前收于9.65美元,开盘报10.10美元。GH Research的股票最新报10.10美元,总成交量为5股。
分析师设定新的价格目标
一些研究分析师最近发布了关于GHRS股票的报告。瑞银集团在12月15日星期四的一份研究报告中对GH Research进行了报道。他们对该股设定了“买入”评级。EF Hutton Acquisition Co.I在12月16日星期五的一份研究报告中发起了对GH Research的报道。他们为该公司设定了“买入”评级和33.00美元的目标价。根据MarketBeat.com的数据,五位股票研究分析师将该股的评级定为买入,目前该股的平均评级为“买入”,平均目标价为46.25美元。
到达GH研究警报:GH Research交易上涨0.1%
该股市值为4.8803亿美元,市盈率为-48.27,贝塔系数为0.96。该公司的50日移动均线切入位在10.40美元,200日移动均线切入位在11.55美元。
GH Research(纳斯达克代码:GHRS-GET Rating)最近一次发布季度收益数据是在11月10日星期四。该公司公布了该季度每股收益(EPS)(0.01美元),比普遍预期的(0.17美元)高出0.16美元。分析师预计,GH Research PLC将公布本财年每股收益为0.42欧元。GH研究的机构交易
对冲基金和其他机构投资者最近对他们在该公司的头寸进行了调整。Tower Research Capital LLC TRC在第三季度将其在GH Research的持股增加了277.1%。Tower Research Capital LLC TRC现在拥有3383股该公司股票,价值3.9万美元,上个季度又购买了2486股。乌龟投资管理有限责任公司在第二季度收购了GH Research的一个新头寸,价值约4.1万美元。交易所交易概念有限公司在第二季度将其在GH Research的头寸增加了373.4%。交易所交易的Concepts LLC现在拥有该公司4,885股股票,价值49,000美元,在上个季度额外收购了3,853股。美国银行DE在第一季度将其在GH Research的头寸提高了31,790.0%。美国银行DE目前持有6,378股该公司股票,价值11.6万美元,此前该公司在上一季度增持了6,358股。最后,Virtus ETF Advisers LLC在第二季度将其在GH Research的头寸提高了48.8%。Virtus ETF Advisers LLC在上个季度增持了3265股后,现在拥有9952股该公司股票,价值9.9万美元。对冲基金和其他机构投资者持有该公司62.55%的股票。
关于生长激素研究
(获取评级)
GH Research PLC是一家临床阶段的生物制药公司,致力于开发治疗精神和神经疾病的各种疗法。该公司专注于开发5-甲氧基-N,N-二甲基色胺(5-MeO-DMT)疗法,用于治疗难治性抑郁症(TRD)。
专题文章
- 免费获取StockNews.com关于生长激素研究的研究报告(GHRS)
- J.B.亨特买房,物流公司成为焦点
- 英特尔股票是否即将突破?
- 人们对百事可乐的新苏打水不感兴趣,这有什么关系吗?
- 阿拉斯加航空能否继续在航空业之上高歌猛进?
- 强生的突破:盈利能提振股市吗?
接受GH研究日报的新闻和评级-在下面输入您的电子邮件地址,以通过MarketBeat.com的免费每日电子邮件时事通讯接收对GH Research和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧